English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Metformin is a synthetic biguanide first described in the 1920´s as a side product of the synthesis of N,N-dimethylguanidine. L ike other related biguanides, metformin displays antihyperglycemic properties, and has become the most widely prescribed oral antidiabeti c medicine around the world. Intriguing recent evidence suggests that metformin has chemopreventive and direct antitumor properties, and s everal ongoing clinical studies around the world are using this agent alone or in combination with chemotherapeutic schemes to determi ne prospectively its safety and efficacy in the treatment of human cancer. Notably, immune activating effects of metformin have re cently been described, and may support a notion put forth in the 1950s that this agent possessed antiviral and antimalarial effects. Howeve r, how these effects may contribute to its observed antitumor effects in retrospective studies has not been discussed. Mechanistically, metf ormin has been shown to activate liver kinase B1 (LKB1) and its downstream target AMP-activated kinase (AMPK). The activation of AMPK has been

Mecanismos antitumorales de la metformina: señalización, metabolismo, inmunidad y más allá.